Information Provided By:
Fly News Breaks for February 25, 2020
Feb 25, 2020 | 09:04 EDT
Craig-Hallum analyst Alexander Nowak raised his price target for Tandem Diabetes to $108 from $92 as he shifts his multiple forward to 2021. The analyst notes Tandem shares were indicating down about 7% as Q4 finished just below the Street, but 2020 guide was a "resounding" beat and the commentary implies an expectation to beat the guide over the year. While t:sport's delay to 2021 is a "disappointment," Nowak would buy the weakness on the longer-term share and pump penetration story. He reiterates a Buy rating on the shares.
News For TNDM From the Last 2 Days
There are no results for your query TNDM